CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net loss	$ (52,600,000)	$ (33,809,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt issuance costs, debt discount, and non-cash interest expense	5,171,000	2,670,000
Stock-based compensation	3,974,000	2,824,000
Change in fair value of financial instruments and hybrid instrument designated at Fair Value Option	1,953,000	2,696,000
Depreciation and amortization expense	1,719,000	1,727,000
Series 3 warrants inducement expense	1,462,000	3,696,000
Loss on extinguishment of debt and conversion of Series D perpetual preferred stock	753,000	1,864,000
ELOC warrants inducement expense	172,000
Amortization of operating lease - right-of-use-asset	94,000	553,000
Derecognition of debt discount on settlement of receivables secured borrowing	49,000
Shares issued in exchange for services	16,000	984,000
Series B convertible preferred stock inducement expense		1,647,000
Expense on modification of warrants		86,000
Shares and warrants issued in Underwriter settlement agreement		76,000
Shares issued as consideration paid under the Oasis Capital Equity Purchase Agreement		33,000
Loss on recourse obligation on secured borrowing		15,000
Interest paid on the conversion of debt to equity		611,000
Shares issued to Atlas for settlement of Trial Delay Fee		612,000
Shares issued on conversion of warrants of Atlas for settlement of Trial Delay Fee		1,904,000
Changes in assets and liabilities
Accounts receivable	2,823,000	(2,840,000)
Other receivable	(407,000)	(26,000)
Inventory	(2,118,000)	(653,000)
Prepaid expenses and other current assets	(796,000)	(955,000)
Other assets	(408,000)	893,000
Accounts payable	158,000	(743,000)
Accrued liabilities	3,034,000	1,194,000
Operating lease liability	(19,000)	(337,000)
Total cash used in operating activities	(34,970,000)	(15,278,000)
Cash flows from investing activities
Purchase of equipment	(6,000)	(7,000)
Total cash used in investing activity	(6,000)	(7,000)
Cash flows from financing activities
Proceeds from issuance of shares in registered public offering, net of issuance and offering costs of $2,550	23,232,000
Proceeds from issuance of notes payable, net of issuance costs of $50 in 2021 and 2020	10,975,000	12,300,000
Proceeds from issuance of shares in At the Market offering, net of issuance and offering costs of $465 in 2021 and offering costs of $78 in 2020	8,595,000	1,281,000
Repayment of receivables secured borrowing	(1,822,000)	(6,207,000)
Proceeds from issuance of shares in PIPE financing	1,751,000	668,000
Repayment of insurance financing	(943,000)	(681,000)
Noncontrolling interest	247,000
Repayment of notes payable	(100,000)	(406,000)
Payment of ELOC warrants offering costs	(35,000)
Proceeds from exercise of stock options	3,000
Proceeds from sale of receivables, net of debt discount and issuance costs of $640		7,057,000
Issuance costs from shares issued on Underwriter settlement agreement		(185,000)
Payments of deferred offering costs		(142,000)
Total cash provided by financing activities	43,937,000	19,492,000
Net increase in cash	8,961,000	4,207,000
Cash at beginning of period	8,090,000	3,883,000
Cash at end of period	17,051,000	8,090,000
Supplemental schedule of cash flow information
Cash paid for interest	28,000	757,000
Supplemental schedule of non-cash financing and investing activities
Shares issued in exchange of partial settlement of royalty interest	2,982,000
Shares issued on exercise of Series 3 warrants	1,776,000	6,057,000
Insurance financing	1,183,000	776,000
Recognition of operating lease - right-of-use asset and operating lease liability	1,087,000	0
Lease modification	91,243	0
Offering costs included in accounts payable and accrued liabilities	13,000
Extinguishment of Series A redeemable convertible preferred stock		11,227,000
Common stock issued as redemption of Series D perpetual preferred stock		6,575,000
Common stock issued as redemption of notes payable and related interest		6,165,000
Shares issued to PoC Capital in payment of contracted research fees		437,000
Total cash	17,051,000	8,090,000
Series 1, Series 2 and Bridge warrant
Cash flows from financing activities
Proceeds from issuance of shares on conversion, net of issuance and offering costs	$ 2,034,000	5,797,000
Supplemental schedule of non-cash financing and investing activities
Deemed dividend		856,000
Common Stock To Oasis Put Exercise
Cash flows from financing activities
Proceeds from issuance of shares on conversion, net of issuance and offering costs		10,000
Series A convertible preferred stock
Supplemental schedule of non-cash financing and investing activities
Accretion to redemption value of Series A contingently redeemable convertible preferred stock		1,332,000
Series B convertible preferred stock
Supplemental schedule of non-cash financing and investing activities
Shares issued on exercise of Series B convertible preferred shares		476,000
Series B-2 Preferred Stock
Supplemental schedule of non-cash financing and investing activities
Conversion of Series B-2 convertible preferred stock into common stock		1,236,000
Series C perpetual preferred stock
Supplemental schedule of non-cash financing and investing activities
Shares issued		4,717,000
Deemed dividend		2,521,000
Accretion to redemption value of Series A contingently redeemable convertible preferred stock		2,521,000
Stock dividend attributable to Series C perpetual preferred stock		130,000
Series D perpetual preferred stock
Supplemental schedule of non-cash financing and investing activities
Shares issued		$ 6,404,000